NovaBridge names Martin Dewhurst as independent director
The Nasdaq-listed biotech added the veteran healthcare executive to its board and to the Audit and Compensation Committees effective September 8, 2026.
SEC filing
Latest
3 stories
Tuesday, September 8
Thursday, August 20
NovaBridge reports H1 2026 results, targets year-end Phase 3 start for givastomig
The company reported $215.9 million in cash and gave updated timelines for its two lead programs, givastomig and VIS-101.
SEC filing
Friday, July 17
NovaBridge Biosciences adopts 2026 Omnibus Share Incentive Plan
The board approved a new equity plan on July 13, 2026, replacing five prior plans and reserving nearly 12 million shares for future awards.
SEC filing